Salivary Gland Neoplasms clinical trials
The registry lists 242 studies for Salivary Gland Neoplasms across more than 10 countries. 29 are recruiting or about to start. 82 of them are mainly about Salivary Gland Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Parotid Neoplasms too: 267 studies, 36 open.
Get an email when these change. Save the Salivary Gland Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (42) · Vanderbilt-Ingram Cancer Center (9) · Dana-Farber Cancer Institute (7) · Memorial Sloan Kettering Cancer Center (6) · Eastern Cooperative Oncology Group (6) · Alliance for Clinical Trials in Oncology (5) · Mayo Clinic (5) · Fox Chase Cancer Center (5)
What is being tested here
Drugs under test in Salivary Gland Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Trastuzumab deruxtecan | 2 | 0 | 2 |
| Ado-Trastuzumab Emtansine | 2 | 0 | 2 |
| Docetaxel | 1 | 1 | 13 |
| Entrectinib | 1 | 0 | 3 |
| Trastuzumab | 1 | 1 | 3 |
| Sacituzumab govitecan | 1 | 0 | 2 |
| Goserelin | 1 | 0 | 2 |
| Sacituzumab tirumotecan | 1 | 0 | 1 |
| Neratinib | 1 | 0 | 1 |
| SX-682 | 1 | 0 | 1 |
Drug classes tested here Antibody-drug conjugates (ADCs) 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Immune checkpoint inhibitors 2 open · Antimitotic agents 1 open · Antimetabolites 17
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers · National Cancer Institute (NCI)
- Dec 2026Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers · Memorial Sloan Kettering Cancer Center
- Dec 2026Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors · Baylor College of Medicine
- Dec 2026Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery · Radiation Therapy Oncology Group
- Dec 2026Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC · OncoC4, Inc.
- Dec 2026A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · Jazz Pharmaceuticals
- Jan 2027A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors · LigaChem Biosciences, Inc.
- Mar 2027Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial · National Cancer Institute (NCI)
- Apr 2027Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients · M.D. Anderson Cancer Center
- May 2027Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) · Merck Sharp & Dohme LLC
Who these studies take
Of the 26 Salivary Gland Neoplasms studies recruiting now, 17 (65%) set no upper age limit and 1 (4%) stop at 75 or younger. 1 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 23 (88%) | 23 (88%) |
| 30 | 26 (100%) | 26 (100%) |
| 40 | 26 (100%) | 26 (100%) |
| 50 | 26 (100%) | 26 (100%) |
| 65 | 26 (100%) | 26 (100%) |
| 75 | 26 (100%) | 26 (100%) |
| 85 | 22 (85%) | 22 (85%) |
Across all 242 studies, recruiting or not: 2% stop at 75 or younger and <1% at 65; 6% take children; 1% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Salivary Gland Neoplasms studies take
Of 45 phase 2 interventional studies under Salivary Gland Neoplasms, half reached primary completion within 59 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 57 mo36–129 · 14 studies | — | — |
| Phase 2 | 59 mo33–94 · 45 studies | — | 59 mo33–90 · 39 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Newly registered1
- Sac-TMT in Salivary Gland CancersNov 10, 2026NCT07928193
Studies
Recruiting first, then most recently updated. Showing 50 of 242. Browse all 242 → or search them.
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/21 country
- Sac-TMT in Salivary Gland CancersNot yet recruitingNCT07928193Phase 21 country
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/22 countries
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingNCT06695845Phase 24 countries
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruitingNCT009004191 country
- PDO Based Drug Sensitive Test in R/M SGCRecruitingNCT066869791 country
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 21 country
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersRecruitingNCT06805617Phase 21 country
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- Abiraterone With Dalpiciclib in Salivary Gland CarcinomaRecruitingNCT07815522Phase 21 country
- Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter StudyRecruitingNCT059465771 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Oropharynx (OPX) Biomarker TrialRecruitingNCT063562721 country
- Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 21 country
- The Head and Neck Registry of the European Reference Network on Rare Adult Solid CancersRecruitingNCT054833743 countries
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 21 country
- Immune Biomarker Study for Salivary Gland CarcinomaRecruitingNCT060472361 country
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsRecruitingNCT03740256Phase 11 country
- Drug Screening Using Novel IMD in Salivary and Head and Neck CancersRecruitingNCT05553782Early Phase 11 country
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/31 country
- Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruitingNCT008986381 country
- A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsRecruitingNCT05941507Phase 1/22 countries
- Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct CarcinomaRecruitingNCT06348264Phase 21 country
- Physiologic MR Imaging of Salivary Gland TumorsRecruitingNCT04452162Not applicable1 country
- Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingNCT06923826Phase 21 country
- Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 MutationsNot yet recruitingNCT06519110Phase 2
- Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma PatientsRecruitingNCT03924466Phase 21 country
- Adenoid Cystic Carcinoma and Carbon Ion Only IrradiationRecruitingNCT04214366Phase 21 country
- Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDCNot yet recruitingNCT05898373Phase 1/2
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 33 countries
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 11 country
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 11 country
- Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer PatientsActive, not recruitingNCT02253238Not applicable1 country
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingNCT04325828Phase 21 country
- Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersActive, not recruitingNCT05884320Phase 21 country
- 9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaActive, not recruitingNCT05010629Phase 21 country
- Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By SurgeryActive, not recruitingNCT01220583Phase 23 countries
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 11 country
- Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 21 country
- Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersActive, not recruitingNCT02749903Phase 21 country
- A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid TumoursActive, not recruitingNCT04969835Phase 12 countries
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/29 countries
- Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By SurgeryCompletedNCT00738868Phase 21 country
- PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation TherapyCompletedNCT00809016Not applicable1 country
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/22 countries
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 216 countries
- Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersActive, not recruitingNCT05669664Phase 21 country
- Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT StudyActive, not recruitingNCT05075980Phase 21 country
- APG-115 in Salivary Gland Cancer TrialActive, not recruitingNCT03781986Phase 1/21 country
- Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive, not recruitingNCT03942653Phase 21 country